GoodRx Holdings, Inc. (GDRX) stock
Close on Nov 17, 2026Market cap $1.18BP/E 86.8Yield –
Earnings
GoodRx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of GoodRx's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $200.40M | -1.3% | $0.02 | $0.08 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026after the close | $194.00M | -4.4% | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $194.80M | -1.9% | $0.02 | $0.09 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025after the close | $196.00M | +0.4% | $0.00 | $0.08 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025after the close | $203.10M | +1.2% | $0.04 | $0.09 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025after the close | $203.00M | +2.6% | $0.03 | $0.09 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $198.60M | +1.0% | $0.02 | $0.09 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $195.30M | +8.5% | $0.01 | $0.08 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $200.60M | +5.7% | $0.02 | $0.08 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | $197.90M | +7.6% | $0.00 | $0.08 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024before the open | $196.60M | +6.8% | -$0.06 | $0.08 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $180.00M | -3.9% | -$0.09 | $0.06 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023before the open | $189.70M | – | $0.14 | $0.07 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023before the open | $184.00M | – | -$0.01 | $0.07 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023after the close | $184.10M | – | $0.00 | $0.07 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $187.30M | – | -$0.10 | $0.07 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022after the close | – | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022after the close | – | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | – | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | – | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
GoodRx's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2026 | $790.00M – $805.00M | $765.00M – $785.00M | Raised | Aug 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $240.00M – $250.00M | $235.00M | Raised | Aug 5, 2026 |
| Revenue YoY Change | FY2026 | -6% – -2% | – | New | Feb 25, 2026 |
Guidance vs results
The last range GoodRx gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue growth | +35% | +0.57%Σ4Q | Below range |
| Q1 FY2025 | Revenue | $201.00M – $205.00M | $203.00M | Within range |
| Q4 FY2024 | Revenue | $200.00M | $198.60M | Below range |
| Q3 FY2024 | Revenue | $193.00M – $197.00M | $195.30M | Within range |
| Q2 FY2024 | Revenue | $200.00M | $200.60M | Above range |
| Q4 FY2023 | Revenue | $195.00M – $197.00M | $196.60M | Within range |
| Q3 FY2023 | Revenue | $186.00M – $190.00M | $180.00M | Below range |
| Q2 FY2023 | Revenue | $185.00M – $188.00M | $189.70M | Above range |
| Q1 FY2023 | Revenue | $181.00M – $183.00M | $184.00M | Above range |
| Q4 FY2022 | Revenue | $175.00M – $180.00M | $184.10M | Above range |
Guidance history
Every forecast GoodRx put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 5, 2026 | Adjusted EBITDA | FY2026 | $240.00M – $250.00M | Raised |
| Aug 5, 2026 | Revenue | FY2026 | $790.00M – $805.00M | Raised |
| May 6, 2026 | Adjusted EBITDA | FY2026 | $235.00M | Raised |
| May 6, 2026 | Revenue | FY2026 | $765.00M – $785.00M | Raised |
| Feb 25, 2026 | Adjusted EBITDA | FY2026 | $230.00M | New |
| Feb 25, 2026 | Revenue YoY Change | FY2026 | -6% – -2% | New |
| Feb 25, 2026 | Revenue | FY2026 | $750.00M – $780.00M | New |
| Nov 4, 2025 | Adjusted EBITDA YoY Change | FY2025 | +2% – +6% | New |
| Nov 4, 2025 | Adjusted EBITDA | FY2025 | $265.00M – $275.00M | New |
| Nov 4, 2025 | Pharma Manufacturer Solutions Revenue Outlook Year-Over-Year Growth | FY2025 | +35% | New |
| Aug 6, 2025 | Adjusted EBITDA YoY Change | FY2025 | +2% – +6% | Lowered |
| Aug 6, 2025 | Adjusted EBITDA | FY2025 | $265.00M – $275.00M | Lowered |
| May 7, 2025 | Adjusted EBITDA YoY Change | FY2025 | +5% – +10% | New |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $273.00M – $287.00M | Raised |
| May 7, 2025 | Revenue YoY Change | FY2025 | +2% – +6% | New |
| May 7, 2025 | Revenue | FY2025 | $810.00M – $840.00M | New |
| Feb 27, 2025 | Adjusted EBITDA | FY2025 | $270.00M – $286.00M | New |
| Feb 27, 2025 | Adjusted EBITDA Margin | Q1 FY2025 | 33% | New |
| Feb 27, 2025 | Revenue | Q1 FY2025 | $201.00M – $205.00M | New |
| Feb 27, 2025 | Revenue | FY2025 | $810.00M – $840.00M | New |
| Nov 7, 2024 | Adjusted EBITDA | FY2024 | $255.00M – $260.00M | Raised |
| Nov 7, 2024 | Adjusted EBITDA Margin | Q4 FY2024 | 34% | New |
| Nov 7, 2024 | Adjusted EBITDA Margin | FY2024 | 32% | New |
| Nov 7, 2024 | Revenue / Adjusted Revenue | Q4 FY2024 | $200.00M | New |
| Nov 7, 2024 | Revenue | FY2024 | $794.00M | Lowered |
| Aug 8, 2024 | Adjusted EBITDA Margin | Q3 FY2024 | 32% | New |
| Aug 8, 2024 | Adjusted EBITDA | FY2024 | $255.00M | Raised |
| Aug 8, 2024 | Revenue | Q3 FY2024 | $193.00M – $197.00M | New |
| Aug 8, 2024 | Adjusted Revenue | Q3 FY2024 | $193.00M – $197.00M | New |
| Aug 8, 2024 | Revenue | FY2024 | $800.00M – $810.00M | Reaffirmed |
| Aug 8, 2024 | Adjusted Revenue | FY2024 | $800.00M – $810.00M | Reaffirmed |
| May 9, 2024 | Adjusted EBITDA | FY2024 | $250.00M | Reaffirmed |
| May 9, 2024 | Revenue | Q2 FY2024 | $200.00M | New |
| May 9, 2024 | Adjusted Revenue | Q2 FY2024 | $200.00M | New |
| May 9, 2024 | Revenue | FY2024 | $800.00M – $810.00M | Raised |
| May 9, 2024 | Adjusted Revenue | FY2024 | $800.00M – $810.00M | Raised |
| Feb 29, 2024 | Adjusted EBITDA | FY2024 | $250.00M | New |
| Feb 29, 2024 | Revenue | FY2024 | $800.00M | New |
| Feb 29, 2024 | Adjusted Revenue | FY2024 | $800.00M | New |
| Jan 10, 2024 | Revenue | Q4 FY2023 | $195.00M – $197.00M | Raised |
| Jan 10, 2024 | Adjusted Revenue | Q4 FY2023 | $195.00M – $197.00M | Raised |
| Jan 10, 2024 | Revenue | FY2023 | $749.00M – $751.00M | Raised |
| Jan 10, 2024 | Adjusted Revenue | FY2023 | $759.00M – $761.00M | Raised |
| Nov 9, 2023 | Revenue | Q4 FY2023 | $188.00M – $194.00M | New |
| Nov 9, 2023 | Adjusted Revenue | Q4 FY2023 | $188.00M – $194.00M | New |
| Nov 9, 2023 | Revenue | FY2023 | $742.00M – $748.00M | Lowered |
| Nov 9, 2023 | Adjusted Revenue | FY2023 | $752.00M – $758.00M | New |
| Aug 9, 2023 | Total Revenue | Q3 FY2023 | $186.00M – $190.00M | New |
| Aug 9, 2023 | Total Revenue | FY2023 | $750.00M – $760.00M | Lowered |
| May 10, 2023 | Total Revenue | Q2 FY2023 | $185.00M – $188.00M | New |
| May 10, 2023 | Total Revenue | FY2023 | $750.00M – $775.00M | New |
| Feb 28, 2023 | total revenue | Q1 FY2023 | $181.00M – $183.00M | New |
| Feb 28, 2023 | total revenue | FY2023 | $780.00M – $790.00M | New |
| Nov 8, 2022 | total revenue | Q4 FY2022 | $175.00M – $180.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases GoodRx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Update
- Update
- Results
- Update
- Results
See a number that looks wrong?